Latest News and Press Releases

Ended second quarter 2021 with $36.8 million in cash and cash equivalents On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., which is subject to the...

CINCINNATI, June 04, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience, Inc. (“Aadi”), a privately-held biopharmaceutical company...

CINCINNATI, May 19, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical company focusing on...

Ended first quarter 2021 with $39.0 million in cash and cash equivalents Subsequent to March 31, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc. CINCINNATI, May ...

Transaction to create Nasdaq-listed company focused on advancing Aadi Bioscience’s late-stage pipeline for genetically-defined cancers with alterations in mTOR pathway genesConcurrent $155 million...

Ended fourth quarter 2020 with $42.6 million in cash and cash equivalents Aerpio is currently evaluating a range of strategic alternatives focused on maximizing stockholder value from existing...

SAN FRANCISCO and CINCINNATI, March 05, 2021 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the...

CINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2,...

Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group. Patient enrollment and dosing continues in both COVID-19 clinical trials ...

Enrollment completed in the 28-day Phase 2 razuprotafib glaucoma trial; topline data expected to be reported in December 2020 or possibly in early January 2021Initiated second clinical trial to...